You are here: Industry Insights > edaravone

News List

Post-Hoc Study Analysis Examines Early Intervention with Edaravone for ALS Survival americanpharmaceuticalreview
March 25, 2021
Mitsubishi Tanabe Pharma America announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous (IV) edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis (ALS).
MTPA Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS americanpharmaceuticalreview
January 08, 2021
Mitsubishi Tanabe Pharma America (MTPA) announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis.
Why Edaravone of Mitsubishi Tanabe is Excellent? PharmaSources/1℃
August 14, 2019
Edaravone of Mitsubishi Tanabe was approved for marketing in China on July 31, 2019, with the acceptance No.: JXHS1900047 and indication of amyotrophic lateral sclerosis (ALS).